Evidence map›Paper›PMID 39670403›Full record

ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2025

Multi-modal Imaging-based Pseudotime Analysis of Alzheimer progression.

Bing He, Shu Zhang, Shannon L Risacher, Andrew J Saykin, Jingwen Yan

Abstract read
In one paragraph

Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bing HeBiomedical Engineering and Informatics, Indiana University Indianapolis, 535 W Michigan St., Indianapolis, Indiana 46202, USA, hebing@iu.edu.
Shu ZhangDepartment of Computer Science, University of California Los Angeles 404 Westwood Plaza Engineering IV, Los Angeles, CA 90095, USA, shuzhang4@g.ucla.edu.
Shannon L RisacherDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, 355 W 15th St., Indianapolis, Indiana 46202, USA, srisache@iu.edu.
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, 355 W 15th St., Indianapolis, Indiana 46202, USA, asaykin@iu.edu.
Jingwen YanBiomedical Engineering and Informatics, Indiana University Indianapolis, 535 W Michigan St., Indianapolis, Indiana 46202, USA, jingyan@iu.edu.

Funding

Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo · 2023 to 2026
$42.0M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
Ultrascale Machine Learning to Empower Discovery in Alzheimers Disease BiobanksU01AG068057 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Christos Davatzikos, Heng Huang · 2020 to 2026
$20.7M
Characterizing the progression of Alzheimer's disease with multi-omic genetic and imaging dataR01AG081951 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI Xiaoqian Wang, Jingwen Yan · 2024 to 2026
$1.9M
Integrative Predictive Modeling of Alzheimer's DiseaseR21AG072101 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI PATANIA, ALICE, YAN, XIAORAN · 2021 to 2021
$446k
NIA NIH HHS P30 AG072976NIA NIH HHS R01 AG081951NIA NIH HHS R21 AG072101NIA NIH HHS U01 AG068057NIA NIH HHS U19 AG074879
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that results in progressive cognitive decline but without any clinically validated cures so far. Understanding the progression of AD is critical for early detection and risk assessment for AD in aging individuals, thereby enabling initiation of timely intervention and improved chance of success in AD trials. Recent pseudotime approach turns cross-sectional data into "faux" longitudinal data to understand how a complex process evolves over time. This is critical for Alzheimer, which unfolds over the course of decades, but the collected data offers only a snapshot. In this study, we tested several state-of-the-art pseudotime approaches to model the full spectrum of AD progression. Subsequently, we evaluated and compared the pseudotime progression score derived from individual imaging modalities and multi-modalities in the ADNI cohort. Our results showed that most existing pseudotime analysis tools do not generalize well to the imaging data, with either flipped progression score or poor separation of diagnosis groups. This is likely due to the underlying assumptions that only stand for single cell data. From the only tool with promising results, it was observed that all pseudotime, derived from either single imaging modalities or multi-modalities, captures the progressiveness of diagnosis groups. Pseudotime from multi-modality, but not the single modalities, confirmed the hypothetical temporal order of imaging phenotypes. In addition, we found that multi-modal pseudotime is mostly driven by amyloid and tau imaging, suggesting their continuous changes along the full spectrum of AD progression.

Indexed as

Alzheimer DiseaseComputational BiologyDisease ProgressionMultimodal ImagingAgedAged, 80 and overCross-Sectional StudiesFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNeuroimagingPositron-Emission Tomography

Identifiers

PMID39670403
PMCPMC12044618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.